{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T15:42:29Z","timestamp":1759938149567,"version":"3.44.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2010,7,3]],"date-time":"2010-07-03T00:00:00Z","timestamp":1278115200000},"content-version":"am","delay-in-days":275,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1016\/j.ygyno.2009.06.012","type":"journal-article","created":{"date-parts":[[2009,7,4]],"date-time":"2009-07-04T04:21:29Z","timestamp":1246681289000},"page":"135-137","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers"],"prefix":"10.1016","volume":"115","author":[{"given":"Danielle","family":"Vicus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Lubinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Domchek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noah D.","family":"Kauff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry T.","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudine","family":"Isaacs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine","family":"Tung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven A.","family":"Narod","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2009.06.012_bb0005","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","article-title":"Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies","volume":"72","author":"Antoniou","year":"2003","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.ygyno.2009.06.012_bb0010","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/jnci\/djj465","article-title":"Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada","volume":"98","author":"Risch","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2009.06.012_bb0015","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.1088759","article-title":"Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2","volume":"302","author":"King","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.ygyno.2009.06.012_bb0020","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ygyno.2004.09.039","article-title":"The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers","volume":"96","author":"Metcalfe","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2009.06.012_bb0025","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/jnci\/86.7.527","article-title":"Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14","volume":"86","author":"Fisher","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2009.06.012_bb0030","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study","volume":"90","author":"Fisher","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2009.06.012_bb0035","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ygyno.2006.08.004","article-title":"The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study","volume":"104","author":"Beiner","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2009.06.012_bb0040","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1001\/jama.288.3.334","article-title":"Menopausal hormone replacement therapy and risk of ovarian cancer","volume":"288","author":"Lacey","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2009.06.012_bb0045","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/S0140-6736(07)60534-0","article-title":"Ovarian cancer and hormone replacement therapy in the Million Women Study","volume":"369","author":"Beral","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2009.06.012_bb0050","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1146\/annurev.pharmtox.37.1.269","article-title":"Molecular mechanisms of genetic polymorphisms of drug metabolism","volume":"37","author":"Meyer","year":"1997","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.ygyno.2009.06.012_bb0055","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1002\/ijc.21536","article-title":"Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update","volume":"118","author":"Gronwald","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ygyno.2009.06.012_bb0060","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1200\/JCO.2004.04.033","article-title":"Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers","volume":"22","author":"Metcalfe","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2009.06.012_bb0065","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1073\/pnas.93.1.316","article-title":"Estrogens increase the expression of fibulin-1, an extracellular matrix protein secreted by human ovarian cancer cells","volume":"93","author":"Clinton","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ygyno.2009.06.012_bb0070","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1210\/edrv-12-1-14","article-title":"Endocrine factors in common epithelial ovarian cancer","volume":"12","author":"Rao","year":"1991","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ygyno.2009.06.012_bb0075","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s11626-996-0015-9","article-title":"BG-1 ovarian cell line: an alternative model for examining estrogen-dependent growth in vitro","volume":"34","author":"Baldwin","year":"1998","journal-title":"In Vitro Cell Dev Biol Anim"},{"key":"10.1016\/j.ygyno.2009.06.012_bb0080","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/1097-0142(19910715)68:2<269::AID-CNCR2820680209>3.0.CO;2-O","article-title":"Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients","volume":"68","author":"Hatch","year":"1991","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2009.06.012_bb0085","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/0090-8258(87)90294-0","article-title":"Tamoxifen therapy in recurrent epithelial ovarian carcinoma","volume":"27","author":"Weiner","year":"1987","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2009.06.012_bb0090","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1006\/gyno.1996.0181","article-title":"Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report","volume":"62","author":"Markman","year":"1996","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2009.06.012_bb0095","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/BF02685901","article-title":"The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer","volume":"24","author":"Karagol","year":"2007","journal-title":"Med Oncol"},{"key":"10.1016\/j.ygyno.2009.06.012_bb0100","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.ygyno.2004.01.035","article-title":"Use of tamoxifen in asymptomatic patients with recurrent small-volume ovarian cancer","volume":"93","author":"Markman","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2009.06.012_bb0105","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1006\/gyno.1996.0011","article-title":"Ovarian tumors in postmenopausal breast cancer patients treated with tamoxifen","volume":"60","author":"Cohen","year":"1996","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2009.06.012_bb0110","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1093\/jnci\/87.18.1359","article-title":"Population-based study of tamoxifen therapy and subsequent ovarian, endome- trial, and breast cancers","volume":"87","author":"Cook","year":"1995","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2009.06.012_bb0115","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/gyno.1999.5378","article-title":"Ovarian histopathology in breast cancer patients receiving tamoxifen","volume":"73","author":"McGonigle","year":"1999","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2009.06.012_bb0120","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s10689-005-4215-3","article-title":"The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation","volume":"4","author":"Metcalfe","year":"2005","journal-title":"Fam Cancer"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825809004648?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825809004648?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:26:00Z","timestamp":1758770760000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825809004648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["S0090825809004648"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2009.06.012","relation":{},"ISSN":["0090-8258"],"issn-type":[{"type":"print","value":"0090-8258"}],"subject":[],"published":{"date-parts":[[2009,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2009.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}